摘要：替奈普酶（TNK）是对阿替普酶进行生物工程改造后基因突变体，与阿替普酶相比，具TNK的纤维蛋白选择性更高、半衰期更长，并且对纤溶酶原激活物抑制剂-1（PAI-1）的抵抗性更强，这使得替奈普酶可单次静脉推注给药，更加方便、快捷。替奈普酶分别在2000年和2001

本期要点

替奈普酶（TNK）是对阿替普酶进行生物工程改造后基因突变体，与阿替普酶相比，具TNK的纤维蛋白选择性更高、半衰期更长，并且对纤溶酶原激活物抑制剂-1（PAI-1）的抵抗性更强，这使得替奈普酶可单次静脉推注给药，更加方便、快捷。

替奈普酶分别在2000年和2001年被美国食品药品监督管理局、欧洲药品管理局批准用于治疗急性ST段抬高型心肌梗死（STEMI）。

近年来，多项临床研究证实替奈普酶在急性缺血性卒中也具有高成功再灌注率，与阿替普酶疗效和安全性相似。随着近期越来越多的证据表明替奈普酶在成功实现再灌注方面的优势以及其实际应用的便捷性，替奈普酶已成为急性缺血性卒中（AIS）溶栓治疗的新潜在选择。

本期内容将与大家一同回顾原研替奈普酶药物开发的历史以及其在急性缺血性脑卒中领域的里程碑式的临床试验。

审批编码：SC-CN-16618

有效期：2026年3月12日

参考文献：

1.Paul Tanswell, et al. Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction. Clin Pharmacokinet. 2002;41(15):1229-45.

2.USAN Council. List No. 422. New names. Tenecteplase. Clin Pharmacol Ther. 1999;66(6):652.

3.Cannon CP, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95(2):351-6.

4.Cannon CP, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998;98(25):2805-14.

5.Van de Werf F, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999;137(5):786-91.

6.Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-22.

7.Haley EC Jr, et al. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36(3):607-12.

8.Haley EC Jr, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707-11.

9.Parsons M, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099-107.

10.Huang X, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14(4):368-76.

11.Huang X, et al. Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials. Int J Stroke. 2016;11(5):534-43.

12.Campbell BCV, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018;378(17):1573-1582.

13.Campbell BCV, et al. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA. 2020;323(13):1257-1265.

14.Logallo N, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781-788.

15.Kvistad CE, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022;21(6):511-519.

16.Menon BK, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.

17.Muir KW, et al. Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol. 2024;23(11):1087-1096.

18.Parsons MW, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial. Lancet Neurol. 2024;23(8):775-786.

19.Meng X, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024;332(17):1437-1445.

20.Alamowitch S, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J. 2023;8(1):8-54.

21.中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023. 中华神经科杂志,2024,57(06)：523-559

审批编码：SC-CN-16618

有效期：2026年3月12日

仅供相关医药专业人士进行医学科学交流

声明：本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

来源：医脉通神经科